Approved in March 2019, esketamine is currently indicated for use alongside an oral antidepressant for treatment-resistant ...
Proceeds expected to support the upcoming planned launches and fund the continued development of Niktimvo and revumenibExpected to fund Syndax through profitability; proforma cash approaching $800 mil ...